FDA 483 - Cilag AG - June 16, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Cilag AG in Schaffhausen, Switzerland, received a Form 483 for significant deficiencies in equipment maintenance, facility design, and aseptic processing controls during drug product manufacturing. Observations included issues with vial capping, sterile assembly design, surface integrity, environmental sealants, and critical surface contamination during fill line setup. Additionally, the firm failed to revalidate critical hold times in SOPs and lacked adequate validation for sterilization equipment.
ID · 537b1473-d6a2-423b-ab58-5fa704f72354